Monte Rosa Therapeutics, Inc.(GLUE)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Monte Rosa Therapeutics, Inc. (GLUE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GLUE at 30.3/100 on a 32-signal composite quality model, placing it at rank #2,494 of 2,961 stocks — the bottom half of the AI-ranked universe. GLUE scores in the top quartile across revenue growth (97.8). Areas of concern include profitability (3.1) and revenue scale (4.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Monte Rosa Therapeutics, Inc. reports quarterly revenue of $9.0M, net income of $-43.4M, free cash flow of $-48.8M. Top institutional holders of GLUE by reported 13-F value include PRICE T ROWE ASSOCIATES, NEA Management Company, BlackRock, based on the most recent SEC filings. GLUE trades on the Nasdaq exchange and files with the SEC under CIK 1826457. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GLUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Monte Rosa Therapeutics, Inc. directly from SEC EDGAR.